Tirzepatide

Description

Tirzepatide (GLP2-T), also designated LY3298176, is a synthetic dual-receptor agonist peptide supplied by AusPepLabs for laboratory and analytical research applications. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.

Tirzepatide is one of the most extensively studied dual incretin receptor agonist peptides in current metabolic research. Its simultaneous engagement of both GIP and GLP-1 receptors makes it a highly relevant reference compound for laboratories investigating dual incretin pathway biology, glucose homeostasis models, and comparative receptor signaling in preclinical settings.

• Dual receptor profile — simultaneous GIP and GLP-1 receptor engagement in research models
• 39 amino acid synthetic peptide with C-20 fatty diacid modification for enhanced stability
• Referenced extensively in peer-reviewed literature across metabolic and endocrine research
• Useful for comparative studies alongside single GLP-1 agonists and triple receptor compounds
• Lyophilized format ensures stability and reproducibility across experimental runs
• Batch and lot identifiers on all labeling for full laboratory documentation compliance

Research Background

GLP2-T (Tirzepatide) has been referenced extensively in scientific literature as a dual GIP/GLP-1 receptor agonist. Preclinical studies in rodent and non-human primate models have examined its effects on glucose regulation, insulin secretion, body weight, and metabolic markers. Phase 3 human clinical trials have been completed and published in peer-reviewed journals. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.